EIQ 4.26% 22.5¢ echoiq limited

Ann: Quarterly Activities Report and Appendix 4C Cash Flow Report, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. RDL
    3,830 Posts.
    lightbulb Created with Sketch. 519
    Yes, it's tight cash flow atm. Further R&D grants get EIQ another 2 quarters+ before needing to worry about cap raising or revenue. It's enough time to get a result from the FDA, bump the share price into the 20's, and raise $10-20m at something like 20-25c. Decent reward from current SP.

    If I recall correctly, reading between the lines somewhat, the FDA requesting further info during the review period is indicative of a positive outcome at the end. Something I took away from the last video call with Prof Strange and Deon Strydom.

    Big quarter ahead with Prof Strange at another conference in London with EIQ as late-breaking news. Then the big one with FDA shortly thereafter.

    A comment on trading - seems some patient hands have been loading up the bids at 15-16c recently and giving the less patient an exit. A drying of supply at the 15-16c range is lining up nicely with the news ahead.


 
watchlist Created with Sketch. Add EIQ (ASX) to my watchlist
(20min delay)
Last
22.5¢
Change
-0.010(4.26%)
Mkt cap ! $132.4M
Open High Low Value Volume
23.5¢ 23.5¢ 22.0¢ $283.0K 1.241M

Buyers (Bids)

No. Vol. Price($)
3 184144 22.0¢
 

Sellers (Offers)

Price($) Vol. No.
23.0¢ 117695 4
View Market Depth
Last trade - 16.10pm 11/11/2024 (20 minute delay) ?
EIQ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.